Oncoclínicas planning new acquisitions and joint venture in 2023
Oncoclínicas planeja novas aquisições e joint venture em 2023
Intel ID : 362202
|
||||
| Intel ID | 362202 | |
| Value | ND | |
| Native Currency |
Brazilian Real (BRL)
Exchange Rate:  |
|
|
Financial Data - Oncoclínicas
(31 Dec 2024) |
Revenue: EUR 972,14m EBITDA: EUR 32,23m Net Debt: EUR 467,81m Exchange Rate: 
|
|
| Date |
|
|
| Country | |
|
| Geography | |
|
| Subsector (Old TTR Sectors) |
|
|
| Primary Subsector (TTRSC) |
30.05.11 Oncology (Primary) 30 Healthcare / 30.05 Specialized Medicine |
|
| Type |
|
|
| Intel Grade |
|
|
| Source |
|
|
| Tags | |
Bidder
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.05.11 Oncology 30 Healthcare / 30.05 Specialized Medicine |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.